{"id":"buspirone-hcl","safety":{"commonSideEffects":[{"rate":"12","effect":"Dizziness"},{"rate":"6","effect":"Headache"},{"rate":"5","effect":"Nervousness"},{"rate":"3","effect":"Lightheadedness"},{"rate":"3","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200399","moleculeType":"Small molecule","molecularWeight":"421.97"},"_dailymed":{"setId":"07a789a9-c9e8-4737-a56d-7d5405fe8100","title":"BUSPIRONE HCL (BUSPIRONE HYDROCHLORIDE) TABLET [ADVAGEN PHARMA LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buspirone selectively binds to and activates serotonin 5-HT1A receptors in the brain, particularly in the raphe nuclei and limbic system, which modulates serotonergic neurotransmission and reduces anxiety symptoms. Unlike benzodiazepines, it does not enhance GABA inhibition, resulting in minimal sedation, muscle relaxation, or anticonvulsant effects, and carries a low potential for abuse or dependence.","oneSentence":"Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety without the sedation or dependence associated with benzodiazepines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:59:26.391Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT04118387","phase":"PHASE4","title":"Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-01-07","conditions":"Sleep Disordered Breathing, Able Bodied","enrollment":200},{"nctId":"NCT04105114","phase":"EARLY_PHASE1","title":"Transformation of Paralysis to Stepping","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Louisville","startDate":"2019-09-30","conditions":"Spinal Cord Injuries","enrollment":15},{"nctId":"NCT04458324","phase":"PHASE2","title":"Hybrid Functional Electrical Stimulation Exercise to Prevent Cardiopulmonary Declines in High-level Spinal Cord Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2020-12-22","conditions":"Spinal Cord Injuries","enrollment":70},{"nctId":"NCT07439042","phase":"PHASE4","title":"Buspirone for Anxiety in Autistic Youth","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-08","conditions":"Anxiety, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT01821690","phase":"PHASE4","title":"Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression","status":"COMPLETED","sponsor":"Indiana University","startDate":"2013-05-15","conditions":"Traumatic Brain Injury","enrollment":81},{"nctId":"NCT03954483","phase":"NA","title":"Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-16","conditions":"Anxiety","enrollment":42},{"nctId":"NCT02313194","phase":"PHASE1, PHASE2","title":"Spinal Cord Neuromodulation for Spinal Cord Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2013-07","conditions":"Cervical Spinal Cord Injury, Tetraparesis, Tetraplegia","enrollment":12},{"nctId":"NCT05511909","phase":"PHASE2","title":"Evaluating Buspirone to Treat Opioid Withdrawal","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-12-15","conditions":"Opioid Use Disorder, Opioid Withdrawal, Opioid Craving","enrollment":100},{"nctId":"NCT05041322","phase":"PHASE2","title":"Improving Ventilatory Capacity in Those With Chronic High Level SCI","status":"COMPLETED","sponsor":"Spaulding Rehabilitation Hospital","startDate":"2020-11-29","conditions":"Spinal Cord Injuries","enrollment":13},{"nctId":"NCT06321341","phase":"PHASE4","title":"Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2024-01-24","conditions":"Vertigo, Autonomic Dysfunction","enrollment":160},{"nctId":"NCT06906224","phase":"EARLY_PHASE1","title":"Effects of Buspirone Combined With Clozapine","status":"COMPLETED","sponsor":"Chuanfu Song","startDate":"2022-05-01","conditions":"Schizophrenia","enrollment":46},{"nctId":"NCT01850355","phase":"NA","title":"An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":"Autism Spectrum Disorders, Anxiety","enrollment":9},{"nctId":"NCT04807517","phase":"PHASE4","title":"Buspirone Treatment of Anxiety in Williams Syndrome","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-08-01","conditions":"Williams Syndrome, Anxiety","enrollment":20},{"nctId":"NCT03432065","phase":"PHASE2","title":"A Pilot Study of Buspirone for the Treatment of Anxiety in Youth with Autism Spectrum Disorders","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2024-12","conditions":"Autism Spectrum Disorder, Anxiety","enrollment":""},{"nctId":"NCT00840606","phase":"PHASE1","title":"Buspirone Hydrochloride 30mg Tablets, Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":"Healthy","enrollment":70},{"nctId":"NCT00840398","phase":"PHASE1","title":"Buspirone Hydrochloride 30mg Tablets, Non-Fasting","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT05629325","phase":"PHASE4","title":"Buspirone for Weak or Absent Esophageal Peristalsis","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-07-06","conditions":"Dysphagia, Esophageal","enrollment":25},{"nctId":"NCT01395953","phase":"PHASE2","title":"Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2011-11","conditions":"Autism Spectrum Disorder (ASD)","enrollment":""},{"nctId":"NCT04400266","phase":"PHASE4","title":"Buspirone and Melatonin for Depression Following Traumatic Brain Injury","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-01","conditions":"Depression, Brain Injuries, Traumatic","enrollment":10},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT06243614","phase":"PHASE3","title":"Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD","status":"RECRUITING","sponsor":"Beijing Union Pharmaceutical Factory Ltd","startDate":"2023-07-24","conditions":"Generalized Anxiety Disorder","enrollment":410},{"nctId":"NCT04052776","phase":"PHASE1","title":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Spinal Cord Injuries, Drug Effect","enrollment":3},{"nctId":"NCT04770454","phase":"","title":"Evaluate the Quality of Life and Treatment of Anxiety Symptoms of Buspirone in Patients With Depression Disorders(BASIS)","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-02-08","conditions":"Depressive Disorder, Major, Anxiety Disorders","enrollment":200},{"nctId":"NCT03587142","phase":"PHASE2","title":"Buspirone for Early Satiety and Symptoms of Gastroparesis","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-08-27","conditions":"Gastroparesis","enrollment":96},{"nctId":"NCT05357547","phase":"PHASE2","title":"Serotonin-receptor Agonism in Reward Processing","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-13","conditions":"Anhedonia","enrollment":63},{"nctId":"NCT02617017","phase":"PHASE3","title":"Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-17","conditions":"Parkinson","enrollment":99},{"nctId":"NCT05430217","phase":"PHASE3","title":"Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2022-01-28","conditions":"Vertigo, Autonomic Dysfunction","enrollment":268},{"nctId":"NCT05377619","phase":"PHASE1, PHASE2","title":"Preventing Gastric Glitch With Prucalopride and Buspirone: N-of-1 Clinical Trial","status":"COMPLETED","sponsor":"Universidade de Passo Fundo","startDate":"2022-01-06","conditions":"Dyspepsia","enrollment":1},{"nctId":"NCT01496612","phase":"PHASE2","title":"Buspirone Therapy for Localized Epilepsy","status":"TERMINATED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2011-11-22","conditions":"Anxiety Disorder, Seizures, Epilepsy","enrollment":9},{"nctId":"NCT02458469","phase":"PHASE2","title":"Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-05-14","conditions":"Spinal Cord Injury, Sleep Disordered Breathing","enrollment":15},{"nctId":"NCT03538431","phase":"PHASE4","title":"Improving Driving in Young People With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-10-31","conditions":"Autism Spectrum Disorder","enrollment":26},{"nctId":"NCT01347541","phase":"PHASE1","title":"Piloting Acute Care to Primary Care Linkage of Safety Net Patients","status":"TERMINATED","sponsor":"University of Washington","startDate":"2011-01","conditions":"Posttraumatic Stress Disorder","enrollment":4},{"nctId":"NCT02589340","phase":"PHASE1","title":"Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2016-01","conditions":"Parkinson's Disease, Dyskinesias, Movement Disorders","enrollment":6},{"nctId":"NCT00270959","phase":"PHASE1","title":"Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-06","conditions":"Post-Traumatic Stress Disorder","enrollment":207},{"nctId":"NCT03521960","phase":"PHASE1","title":"Buspirone for Opioid Tapering","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-05-30","conditions":"Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic","enrollment":18},{"nctId":"NCT04352686","phase":"NA","title":"Effects of Serotonin Agonist Buspirone on Multimodal Esophageal Stimulation in Healthy Volunteers","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-02","conditions":"Gastroesophageal Reflux","enrollment":10},{"nctId":"NCT02803749","phase":"PHASE2","title":"Buspirone in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2016-10","conditions":"Parkinson Disease, Anxiety","enrollment":21},{"nctId":"NCT01833312","phase":"PHASE3","title":"Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2013-07","conditions":"Acute Ischemic Stroke","enrollment":98},{"nctId":"NCT02483598","phase":"PHASE4","title":"Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone","status":"TERMINATED","sponsor":"North Dakota State University","startDate":"2015-06","conditions":"Gastric Bypass","enrollment":12},{"nctId":"NCT02674412","phase":"NA","title":"Buspirone for Functional Dysphagia","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-02","conditions":"Functional Dysphagia, Ineffective Esophageal Motility","enrollment":10},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT03444831","phase":"PHASE4","title":"Buspirone Plus Omeprazole for Functional Dyspepsia","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","startDate":"2016-03-01","conditions":"Dyspepsia","enrollment":70},{"nctId":"NCT01843205","phase":"PHASE1","title":"Buspirone as a Candidate Medication for Methamphetamine Abuse","status":"COMPLETED","sponsor":"University of Kentucky","startDate":"2013-04","conditions":"Methamphetamine Dependence, Methamphetamine Abuse","enrollment":9},{"nctId":"NCT00652730","phase":"PHASE1","title":"Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"1998-07","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":21},{"nctId":"NCT00178971","phase":"PHASE3","title":"Serotonin 1A Agonists and Cognition in Schizophrenia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2003-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":60},{"nctId":"NCT02132832","phase":"PHASE2","title":"Buspirone, Stress, and Attentional Bias to Marijuana Cues","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2013-06","conditions":"Cannabis Use Disorder","enrollment":45},{"nctId":"NCT01267292","phase":"PHASE2","title":"Psychopharmacology for Cocaine Dependence - Buspirone","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-03","conditions":"Cocaine Dependence","enrollment":50},{"nctId":"NCT01123161","phase":"PHASE2, PHASE3","title":"The Intravascular Cooling in the Treatment of Stroke 2/3 Trial","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2010-06","conditions":"Stroke, Acute","enrollment":120},{"nctId":"NCT00326235","phase":"PHASE4","title":"Effects of Buspirone in Opiate Withdrawal","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2002-01","conditions":"Heroin Dependence","enrollment":""},{"nctId":"NCT02363478","phase":"EARLY_PHASE1","title":"Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)","status":"COMPLETED","sponsor":"Laikο General Hospital, Athens","startDate":"2014-12","conditions":"Systemic Sclerosis","enrollment":22},{"nctId":"NCT00875836","phase":"PHASE4","title":"Buspirone Treatment for Marijuana Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-09","conditions":"Marijuana Dependence","enrollment":175},{"nctId":"NCT00873509","phase":"PHASE2, PHASE3","title":"Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder","status":"COMPLETED","sponsor":"Chugani, Diane C.","startDate":"2009-05","conditions":"Autistic Disorder","enrollment":166},{"nctId":"NCT00334360","phase":"PHASE4","title":"Dexmed/Buspirone Synergism on Shivering","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2004-09","conditions":"Hypothermia","enrollment":8},{"nctId":"NCT00746954","phase":"PHASE3","title":"Buspirone as a Potential Treatment for Recurrent Central Apnea","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2008-09","conditions":"Central Apnea, Heart Failure","enrollment":8},{"nctId":"NCT01639157","phase":"NA","title":"Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine","status":"COMPLETED","sponsor":"William Stoops","startDate":"2012-09","conditions":"Cocaine Use Disorders","enrollment":9},{"nctId":"NCT00053846","phase":"PHASE2, PHASE3","title":"Buspirone in Reducing Shortness of Breath in Patients With Cancer","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2002-11","conditions":"Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":432},{"nctId":"NCT00149617","phase":"PHASE2","title":"Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2004-04","conditions":"Marijuana Abuse, Mood Disorders","enrollment":81},{"nctId":"NCT01484184","phase":"PHASE1, PHASE2","title":"Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury","status":"COMPLETED","sponsor":"Nordic Life Science Pipeline Inc.","startDate":"2013-07","conditions":"Spinal Cord Injury","enrollment":50},{"nctId":"NCT01546896","phase":"PHASE4","title":"Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","startDate":"2012-03","conditions":"Anxiety Disorder","enrollment":""},{"nctId":"NCT02101203","phase":"PHASE2","title":"Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder","status":"COMPLETED","sponsor":"Emotional Brain NY Inc.","startDate":"2013-07","conditions":"Hypoactive Sexual Desire Disorder","enrollment":80},{"nctId":"NCT01641159","phase":"PHASE2","title":"Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2012-08","conditions":"Cocaine Dependence","enrollment":62},{"nctId":"NCT02273154","phase":"PHASE4","title":"Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder","status":"UNKNOWN","sponsor":"Si Tianmei","startDate":"2014-08","conditions":"Major Depression Disorder","enrollment":240},{"nctId":"NCT02186366","phase":"NA","title":"Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type","status":"UNKNOWN","sponsor":"Sun Qing","startDate":"2014-09","conditions":"Anxiety Disorders","enrollment":140},{"nctId":"NCT00705003","phase":"PHASE2","title":"Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-05","conditions":"Major Depressive Disorder","enrollment":142},{"nctId":"NCT01699828","phase":"PHASE1, PHASE2","title":"Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2012-10","conditions":"Smoking Cessation, Tobacco Use Cessation","enrollment":6},{"nctId":"NCT01743235","phase":"PHASE2","title":"Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems","status":"COMPLETED","sponsor":"Emotional Brain NY Inc.","startDate":"2012-07","conditions":"Hypoactive Sexual Desire Disorder","enrollment":207},{"nctId":"NCT01379313","phase":"NA","title":"The Effect of Different I:E Ratio on Gas Exchange of Patients Undergoing Gynecologic Laparoscopic Surgery With Trendelenburg Position","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Uterine Myoma, Ovarian Cyst, Laparoscopic Gynecologic Surgery","enrollment":100},{"nctId":"NCT00360191","phase":"PHASE2","title":"A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2004-04","conditions":"Marijuana Abuse","enrollment":81},{"nctId":"NCT00166621","phase":"PHASE1, PHASE2","title":"Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy","status":"COMPLETED","sponsor":"Chugani, Diane C.","startDate":"2004-03","conditions":"Autism","enrollment":20},{"nctId":"NCT00021528","phase":"PHASE4","title":"Sequenced Treatment Alternatives to Relieve Depression (STAR*D)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2001-07","conditions":"Depression","enrollment":4000},{"nctId":"NCT00174226","phase":"PHASE2","title":"Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":241},{"nctId":"NCT00653419","phase":"PHASE1","title":"Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"1998-06","conditions":"To Determine Bioequivalence Under Fasting Conditions","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20160229","type":"SUPPL","sponsor":"RUBICON RESEARCH","applicationNumber":"ANDA075521"},{"date":"20030103","type":"SUPPL","sponsor":"RUBICON RESEARCH","applicationNumber":"ANDA075521"},{"date":"20020405","type":"ORIG","sponsor":"RUBICON RESEARCH","applicationNumber":"ANDA075521"},{"date":"20210303","type":"SUPPL","sponsor":"RUBICON RESEARCH","applicationNumber":"ANDA075521"},{"date":"20200528","type":"SUPPL","sponsor":"RUBICON RESEARCH","applicationNumber":"ANDA075521"}],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Buspar"],"phase":"marketed","status":"active","brandName":"Buspirone HCl","genericName":"Buspirone HCl","companyName":"Par Pharmaceutical, Inc.","companyId":"par-pharmaceutical-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buspirone acts as a serotonin 5-HT1A receptor agonist to reduce anxiety without the sedation or dependence associated with benzodiazepines. Used for Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2002-04-05T00:00:00.000Z","mah":"RUBICON RESEARCH","brand_name_local":null,"application_number":"ANDA075521"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}